Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Tarantino, Paolo"'
Autor:
Dinkel J; Department of Radiology, University Hospital LMU Munich, Munich, Germany. julien.dinkel@gmail.com.; Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany. julien.dinkel@gmail.com., Kneidinger N; Department of Medicine V, Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Germany.; Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., Tarantino P; Breast Oncology Center, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy.
Publikováno v:
Insights into imaging [Insights Imaging] 2024 Aug 01; Vol. 15 (1), pp. 191. Date of Electronic Publication: 2024 Aug 01.
Autor:
Nicolò E; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy; Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA., Gandini S; Molecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy., Giugliano F; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy., Uliano J; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy., D'Ecclesiis O; Molecular and Pharmaco-Epidemiology Unit, Department of Experimental Oncology, European Institute of Oncology, IRCCS, Milan, Italy., Morganti S; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ferraro E; Breast Cancer Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Trapani D; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy., Tarantino P; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Zagami P; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy., Boldrini L; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy., Caramella I; Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy., Carnevale Schianca A; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy., Cristofanilli M; Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA., Locatelli MA; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy., Esposito A; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy., Belli C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy., Minchella I; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy., Criscitiello C; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy., Marra A; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy., Curigliano G; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Aug; Vol. 207, pp. 114181. Date of Electronic Publication: 2024 Jun 17.
Autor:
Scafuri L; Oncology Unit, 'Andrea Tortora' Hospital, ASL Salerno, Pagani, Italy. lucaluca@hotmail.it.; Associazione O.R.A. ETS-Oncology Research Assistance, Salerno, Italy. lucaluca@hotmail.it., Buonerba C; Oncology Unit, 'Andrea Tortora' Hospital, ASL Salerno, Pagani, Italy.; Associazione O.R.A. ETS-Oncology Research Assistance, Salerno, Italy., Di Lauro V; Department of Breast & Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy., Tortora V; S.C. Oncologia, ASL Vercelli, Vercelli, Italy., Cascella M; Anesthesia and Pain Medicine, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Via S. Allende, 84081, Baronissi, Italy., Liguori L; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy., Sciarra A; Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, NA, Italy., Sabbatino F; Oncology Unit, Department of Medicine, Surgery and Dentistry, University of Salerno, 84081, Baronissi, Salerno, Italy., Diana A; Medical Oncology Unit, Ospedale del Mare, Naples, Italy., Marra A; European Institute of Oncology-IRCCS, Milan, Italy., Tarantino P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Trapani D; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology-IRCCS, Milan, Italy., Giuliano M; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy., Arpino G; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy., Curigliano G; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.; Division of Early Drug Development for Innovative Therapy, European Institute of Oncology-IRCCS, Milan, Italy., Di Lorenzo G; Oncology Unit, 'Andrea Tortora' Hospital, ASL Salerno, Pagani, Italy.; Associazione O.R.A. ETS-Oncology Research Assistance, Salerno, Italy.
Publikováno v:
Oncology and therapy [Oncol Ther] 2024 Jun 28. Date of Electronic Publication: 2024 Jun 28.
Autor:
Tarantino P; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Tayob N; Harvard Medical School, Boston, MA.; Division of Data Science, Dana-Farber Cancer Institute, Boston, MA., Villacampa G; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Oncology Data Science Vall d'Hebron Institute of Oncology, Barcelona, Spain., Dang C; Memorial Sloan Kettering Cancer Center, New York, NY., Yardley DA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN., Isakoff SJ; Harvard Medical School, Boston, MA.; Massachusetts General Hospital, Boston, MA., Valero V; MD Anderson Cancer Center, Houston, TX., Faggen M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Mulvey T; Harvard Medical School, Boston, MA.; Massachusetts General Hospital, Boston, MA., Bose R; Washington University School of Medicine, St Louis, MO., Weckstein D; New Hampshire Oncology Hematology, Manchester, NH., Wolff AC; Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC., Reeder-Hayes K; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Rugo HS; University of California, San Francisco, CA., Ramaswamy B; Ohio State University Comprehensive Cancer Center, Columbus, OH., Zuckerman D; St Luke's Mountain States Tumor Institute, Boise, ID., Hart L; Wake Forest Baptist Health, Winston-Salem, NC., Gadi VK; University of Illinois Cancer Center, Chicago, IL., Constantine M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Cheng K; North Shore-LIJ Cancer Institute, Lake Success, NY., Garrett AM; Northern Light Cancer Care, Brewer, ME., Marcom PK; Duke University School of Medicine, Durham, NC., Albain K; Loyola University Medical Center, Maywood, IL., DeFusco P; Hartford Healthcare Cancer Institute, Hartford, CT., Tung N; Harvard Medical School, Boston, MA.; Beth Israel Deaconess Medical Center, Boston, MA., Ardman B; Lowell General Hospital, Lowell, MA., Nanda R; UChicago Medicine, Chicago, IL., Jankowitz RC; Perelman Center for Advanced Medicine, Philadelphia, PA., Rimawi M; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Abramson V; Vanderbilt-Ingram Cancer Center, Nashville, TN., Pohlmann PR; MD Anderson Cancer Center, Houston, TX.; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC., Van Poznak C; Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Forero-Torres A; Kirklin UAB Hematology Oncology, Birmingham, AL., Liu MC; Natera, Inc, Austin, TX., Ruddy KJ; Mayo Clinic, Rochester, NY., Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., DeMeo M; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA., Burstein HJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Dell'Orto P; IEO European Institute of Oncology, IRCCS, Milan, Italy., Russo L; IEO European Institute of Oncology, IRCCS, Milan, Italy., Krause E; PathAI, Boston, MA., Newhouse DJ; NanoString Technologies, Inc, Boston, MA., Kurt BB; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA., Schneider B; Indiana University School of Medicine, Indianapolis, IN., Prat A; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain., Winer EP; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Yale Cancer Center, New Haven, CT., Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Yale Cancer Center, New Haven, CT., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jun 27, pp. JCO2302170. Date of Electronic Publication: 2024 Jun 27.
Autor:
Corso G; Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy; Department of Oncology and Hematology, University of Milano, Milan, Italy., Fusco N; Department of Oncology and Hematology, University of Milano, Milan, Italy; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy., Guerini-Rocco E; Department of Oncology and Hematology, University of Milano, Milan, Italy; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy., Leonardi MC; Division of Radiation Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy., Criscitiello C; Department of Oncology and Hematology, University of Milano, Milan, Italy; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy., Zagami P; Department of Oncology and Hematology, University of Milano, Milan, Italy; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy., Nicolò E; Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY, USA., Mazzarol G; Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy., La Vecchia C; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy., Pesapane F; Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy., Zanzottera C; Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, Milan, Italy., Tarantino P; Department of Oncology and Hematology, University of Milano, Milan, Italy; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA; Harvard Medical School, Boston, MA., Petitto S; Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy., Bianchi B; Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy., Massari G; Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy., Boato A; Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy., Sibilio A; Division of Breast Surgery Forlì (Ravenna), AUSL Romagna, Ravenna, Italy., Polizzi A; Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy., Curigliano G; Department of Oncology and Hematology, University of Milano, Milan, Italy; Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy., De Scalzi AM; Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy., Lauria F; Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy., Bonanni B; Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, Milan, Italy., Marabelli M; Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, Milan, Italy., Rotili A; Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy., Nicosia L; Breast Imaging Division, IEO European Institute of Oncology IRCCS, Milan, Italy., Albini A; Scientific Directorate, European Institute of Oncology (IEO), IRCCS, Milan, Italy., Calvello M; Division of Cancer Prevention and Genetics, IEO European Institute of Oncology IRCCS, Milan, Italy; Division of Hematology, Clinica Moncucco, Lugano, Switzerland., Mukhtar RA; Department of Surgery, Division of Surgical Oncology, University of California San Francisco, San Francisco, CA., Robson ME; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY., Sacchini V; Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy; Department of Oncology and Hematology, University of Milano, Milan, Italy., Rennert G; B. Rappaport Faculty of Medicine, Technion and the Association for Promotion of Research in Precision Medicine (APRPM), Haifa, Israel., Galimberti V; Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy., Veronesi P; Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy; Department of Oncology and Hematology, University of Milano, Milan, Italy., Magnoni F; Division of Breast Surgery, European Institute of Oncology (IEO), IRCCS, Milan, Italy. Electronic address: francesca.magnoni@ieo.it.
Publikováno v:
Seminars in oncology [Semin Oncol] 2024 Jun-Aug; Vol. 51 (3-4), pp. 106-122. Date of Electronic Publication: 2024 May 20.
Autor:
Lynce F; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu., Mainor C; MedStar Georgetown University Hospital, Washington, DC, USA., Donahue RN; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Geng X; Georgetown University, Washington, DC, USA., Jones G; NeoGenomics, Durham, NC, USA., Schlam I; MedStar Washington Hospital Center, Washington, DC, USA.; Tufts Medical Center, Boston, MA, USA., Wang H; Georgetown University, Washington, DC, USA., Toney NJ; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Jochems C; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Schlom J; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zeck J; MedStar Georgetown University Hospital, Washington, DC, USA., Gallagher C; MedStar Washington Hospital Center, Washington, DC, USA., Nanda R; University of Chicago, Chicago, IL, USA., Graham D; Hackensack University Medical Center, Hackensack, NJ, USA., Stringer-Reasor EM; University of Alabama at Birmingham, Birmingham, AL, USA., Denduluri N; AstraZeneca, Arlington, VA, USA., Collins J; MedStar Georgetown University Hospital, Washington, DC, USA.; AstraZeneca, Arlington, VA, USA., Chitalia A; MedStar Washington Hospital Center, Washington, DC, USA., Tiwari S; MedStar Washington Hospital Center, Washington, DC, USA., Nunes R; Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA.; AstraZeneca, Arlington, VA, USA., Kaltman R; Inova, Fairfax, VA, USA., Khoury K; University of Alabama at Birmingham, Birmingham, AL, USA., Gatti-Mays M; The Ohio State University, Columbus, OH, USA., Tarantino P; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Tolaney SM; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Swain SM; Georgetown University, Washington, DC, USA., Pohlmann P; MedStar Georgetown University Hospital, Washington, DC, USA., Parsons HA; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Isaacs C; Georgetown University, Washington, DC, USA.
Publikováno v:
Nature communications [Nat Commun] 2024 May 10; Vol. 15 (1), pp. 3957. Date of Electronic Publication: 2024 May 10.
Autor:
Tarantino P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy., Leone J; Grupo Oncológico Cooperativo del Sur, Neuquén, Argentina., Vallejo CT; Grupo Oncológico Cooperativo del Sur, Neuquén, Argentina., Freedman RA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Waks AG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Martínez-Sáez O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Garrido-Castro A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Lynce F; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Tayob N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Leone JP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. JoseP_Leone@dfci.harvard.edu.
Publikováno v:
NPJ breast cancer [NPJ Breast Cancer] 2024 Apr 04; Vol. 10 (1), pp. 26. Date of Electronic Publication: 2024 Apr 04.
Autor:
Tarantino P; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy. Electronic address: paolo_tarantino@dfci.harvard.edu., Ajari O; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Graham N; Harvard Medical School, Boston, MA, USA; Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Vincuilla J; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Parker T; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Hughes ME; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA., Tayob N; Harvard Medical School, Boston, MA, USA; Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA., Garrido-Castro AC; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Morganti S; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., King TA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA., Curigliano G; Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy; European Institute of Oncology IRCCS, Milan, Italy., Lin NU; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 Apr; Vol. 201, pp. 113920. Date of Electronic Publication: 2024 Feb 10.
Autor:
Lynce F; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Filipa_Lynce@dfci.harvard.edu., Mainor C; MedStar Georgetown University Hospital, Washington, DC, USA., Donahue RN; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Geng X; Georgetown University, Washington, DC, USA., Jones G; NeoGenomics, Durham, NC, USA., Schlam I; MedStar Washington Hospital Center, Washington, DC, USA.; Tufts Medical Center, Boston, MA, USA., Wang H; Georgetown University, Washington, DC, USA., Toney NJ; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Jochems C; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Schlom J; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zeck J; MedStar Georgetown University Hospital, Washington, DC, USA., Gallagher C; MedStar Washington Hospital Center, Washington, DC, USA., Nanda R; University of Chicago, Chicago, IL, USA., Graham D; Hackensack University Medical Center, Hackensack, NJ, USA., Stringer-Reasor EM; University of Alabama at Birmingham, Birmingham, AL, USA., Denduluri N; AstraZeneca, Arlington, VA, USA., Collins J; MedStar Georgetown University Hospital, Washington, DC, USA.; AstraZeneca, Arlington, VA, USA., Chitalia A; MedStar Washington Hospital Center, Washington, DC, USA., Tiwari S; MedStar Washington Hospital Center, Washington, DC, USA., Nunes R; Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA.; AstraZeneca, Arlington, VA, USA., Kaltman R; Inova, Fairfax, VA, USA., Khoury K; University of Alabama at Birmingham, Birmingham, AL, USA., Gatti-Mays M; The Ohio State University, Columbus, OH, USA., Tarantino P; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Tolaney SM; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Swain SM; Georgetown University, Washington, DC, USA., Pohlmann P; MedStar Georgetown University Hospital, Washington, DC, USA., Parsons HA; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Isaacs C; Georgetown University, Washington, DC, USA.
Publikováno v:
Nature communications [Nat Commun] 2024 Mar 27; Vol. 15 (1), pp. 2691. Date of Electronic Publication: 2024 Mar 27.
Autor:
De Matteis E; U.O.S.V.D. Oncological Screenings, 'Vito Fazzi' Hospital, Lecce, Italy., Tumolo MR; Department of Biological and Environmental Sciences and Technology, University of Salento, Lecce, Italy., Tarantino P; U.O.C. Medical Genetics, 'Vito Fazzi' Hospital, Lecce, Italy., Ciccarese M; Strategic Regional Agency for Health and Social of Puglia, Bari, Italy., Grassi T; Department of Biological and Environmental Sciences and Technology, University of Salento, Lecce, Italy., Bagordo F; Department of Pharmacy-Pharmaceutical Sciences, University of Bari 'Aldo Moro', Bari, Italy., De Giorgio MR; U.O.S.V.D. Oncological Screenings, 'Vito Fazzi' Hospital, Lecce, Italy., Rizzo E; Department of Biological and Environmental Sciences and Technology, University of Salento, Lecce, Italy., Ronzino G; Oncology Unit, 'Vito Fazzi' Hospital, Lecce, Italy.
Publikováno v:
Oncotarget [Oncotarget] 2024 Feb 22; Vol. 15, pp. 134-141. Date of Electronic Publication: 2024 Feb 22.